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Abstract – We investigated changes in bone mineral density (BMD) and relevant factors of BMD in patients with type 1 
diabetes (T1D). A total of 47 patients with T1D and 40 healthy controls participated in this study. The waist-to-hip ratio 
(WHR) and body mass index (BMI) were calculated after physical examination. The lumbar spine (L2-L4) BMD and left 
femoral neck BMD were examined. Blood samples were collected. The BMI, WHR, fasting C peptide (FCP), postprandial 
C peptide (2hCP), lumbar spine and left femoral neck BMD of the patients with T1D were significantly lower than those 
of healthy controls, while the fasting plasma glucose (FPG), postprandial plasma glucose (2hPG) and hemoglobin A1c 
(HbA1c) were higher (P <0.05). Duration of T1D and HbA1c were negatively correlated with lumbar spine and left femo-
ral neck BMD. The FCP and 2hCP were positively correlated with lumbar spine and left femoral neck BMD. 
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INTRODUCTION
The incidences of diabetes and osteoporosis have in-
creased and diabetic patients with a high prevalence 
of osteoporosis are gradually attracting more atten-
tion (Watanabe and Okazaki, 2012). There are com-
plex relationships between diabetes and osteoporosis. 
Patients with T1D have a greater risk of fracture since 
they cannot reach their potential peak bone mass 
(Sealand et al., 2013). The change in the bone min-
eral density (BMD) of patients with T1D has always 
been disputed. It has been reported that the patients 
with type 2 diabetes (T2D) have reduced, increased 
or unchanged BMD (Brown SA, 2004; Abdulameer 
et al., 2012; Chen et al., 2013). Several studies have 
reported that patients with T1D have increased bone 
fracture risk and decreased BMD (Vestergaard, 2007; 
Eller-Vainicher et al., 2011). 
The increased risk of osteoporotic fracture is re-
lated to the history of diabetes, diabetes duration and 
chronic complications (Rakic et al., 2006; Schneider 
et al., 2012). Meanwhile the risk of bone fracture is 
related to glycemic control, and the etiologies remain 
elusive (Neumann et al., 2011; Simmons et al., 2011). 
What’s  more,  hyperglycemia,  autoimmune  inflam-
mation, hyperinsulinemia, hypoamylinemia, deficit 
of insulin-like growth factors-I (IGF-I) and vitamin 
D may be the potential pathogenic mechanisms of 
T1D (Moyer-Mileur et al., 2008; Coe et al., 2011; 
Takeuchi, 2012). Although osteoporosis is one of the 
complications of T1D, there are few studies about the 
BMD of patients with T1D in China. 
In recent years, research about the BMD of pa-
tients with T2D is gradually increasing in China and 
abroad, while there is relatively less researche about 1092 PENG DUAN ET AL.
T1D. The aim of this study was to investigate BMD 
changes in patients with T1D and the association 
between BMD and factors such as the course of the 
diabetes, hemoglobin A1c, fasting C peptide, fast-
ing plasma glucose, 2 h postprandial plasma glucose 
and 2 h postprandial C peptide. In our study, we col-
lected forty-seven patients with T1D to investigate 
the changes in BMD and factors relevant related to 
BMD, using classical statistical methods.
MATERIALS AND METHODS
Study population
Patients  with  T1D  were  recruited  from  inpatients 
and outpatients in the incretion department of the 
Third Hospital of Nanchang from February 2010 to 
February  2012.  All  patients  enrolled  in  our  study 
conformed to the 1999 World Health Organization 
criteria for diagnosis of T1D. Healthy people with 
normal blood glucose from the physical examination 
center of the Third Hospital of Nanchang and the 
investigation  of  epidemiology  in  community  were 
taken as controls. The study protocol was explained 
to both cases and controls before participation, and 
informed consent was obtained from each partici-
pant prior to the start of the study.
Assay methods
General information of the study population, such as 
gender, age, education level, vocation, marriage sta-
tus, income, duration of diabetes and complications 
was collected. The height, weight, waist and hip of 
all participants were measured by physical examina-
tion, and the BMI (kg/m2) and WHR were calculat-
ed. Dual-energy X-ray absorptiometry (MEDILINK, 
France) was used to measure the lumbar spine (L2-
L4)  BMD  and  left  femoral  neck  BMD.  All  of  the 
measurements were completed with the same instru-
ment and operator.
Fasting blood samples of the patients with T1D 
were collected to measure the levels of FPG, HbA1c 
and FCP. The levels of 2hPG and 2hCP were detected 
2 h after eating 100 g of steamed bread. The control 
group underwent the oral glucose tolerance test. The 
fasting blood and the 2 h post-meal blood were col-
lected to measure the biochemical parameters. The 
venous blood glucose was determined by the method 
of glucose oxidase using an automatic biochemical 
analyzer  (ADVIA2400,  Siemens).  Plasma  C  pep-
tide was measured using the radiate immune assay 
kit (Shandong 3V, China). HbA1c was detected by 
high efficiency liquid chromatography using an au-
tomatic glycosylated hemoglobin meter (BIO-RAD, 
America).
Statistical analysis
Statistical analysis was performed by SPSS ver. 13.0 
statistical software (SPSS, Chicago, IL), and data were 
expressed as means ± SD. One-way ANOVA or two 
independent T-tests were used to analyze all data of 
the healthy controls and patients with T1D. Pearson’s 
correlation coefficient was used to indicate the cor-
relation. Multiple-factor analysis was performed us-
ing the multiple stepwise regression method. There is 
significantly statistical difference when P <0.05.
RESULTS
The study population included 47 patients with T1D 
and 40 healthy controls. The mean duration of di-
abetes was 7.21±3.97 years, and the average age of 
participants in the T1D and control groups had no 
obvious difference (20.19±5.21 vs. 21.41±5.39 years, 
P >0.05). Differences in demographic, physical and 
biochemical variables between the T1D and control 
groups are shown in Table 1. The BMI, WHR, FCP, 
2hCP, lumbar spine and left femoral neck BMD of 
the diabetic patients were significantly lower than 
those  of  the  control  subjects  (P  <0.05),  while  the 
FPG, 2hPG and HbA1c of the diabetic group were 
increased (P <0.05). Since there was a significant dif-
ference in the BMI between the two groups, the data 
were further analyzed by one-way ANOVA after BMI 
was adjusted. The results indicated that FCP, 2hCP 
and BMD of the diabetic group were still lower than 
those of the control group, while the FPG, 2hPG and 
HbA1c of the diabetic group were significantly in-
creased (P <0.05).BONE MINERAL DENSITy IN DIABETES 1093
Pearson’s analysis for the BMD of T1D patients 
and relevant factors found that the duration of diabe-
tes (r = -0.145, P = 0.002; r = -0.161, P = 0.000) and 
HbA1c (r = -0.141, P = 0.001; r = -0.203, P = 0.000) 
were negatively correlated to lumbar spine BMD and 
left femoral neck BMD, while FCP (r = 0.312, P = 
0.000; r = 0.340, P = 0.000) and 2hCP (r = 0.261; P 
= 0.000; r = 0.272, P = 0.000) showed positively cor-
Table 1. Demographic, physical and biochemical variables of T1D patients and control subjects (Data are shown as means ± SD, * P < 
0.05 vs. control group)
Variables Type 1 diabetes Control
Number 47 40
Age (years) 20.190 ± 5.210 21.410 ± 5.390
BMI (kg/m2) 21.260 ± 3.140* 24.400 ± 3.500
WHR 0.770 ± 0.150* 0.830 ± 0.220
HbA1c (%) 8.100 ± 1.900* 5.100 ± 0.600
FPG (mmol/L) 8.500 ± 2.100* 5.20 0± 0.800
2hPG (mmol/L) 12.520 ± 3.170* 6.720 ± 1.030
FCP (ng/ml) 0.230 ± 0.100* 1.860 ± 0.630
2hCP (ng/ml) 0.320 ± 0.150* 5.410 ± 1.890
lumbar spine (L2-L4) BMD (mg/cm3) 0.822 ± 0.083* 0.885 ± 0.086
left femoral neck BMD (mg/cm3) 0.813 ± 0.090* 0.877 ± 0.098
Table 2. The Pearson analysis of BMD and relevant factors in patients with T1D and relevant factors
Lumbar spine BMD Left femoral neck BMD
Age r value 0.028 0.033
P value 0.326 0.347
Diabetic duration
r value -0.145 -0.161
P value 0.002 0.000
BMI r value 0.012 0.020
P value 0.561 0.478
HbA1c
r value -0.141 -0.203
P value 0.001 0.000
FPG r value -0.079 0.052
P value 0.073 0.196
2hPG r value -0.035 -0.055
P value 0.166 0.249
FCP
r value 0.312 0.340
P value 0.000 0.000
2hCP
r value 0.261 0.272
P value 0.000 0.000
Table 3. The multiple regression analysis of BMD and relevant factors in patients with T1D 
Age
Diabetic 
duration
BMI HbA1c FPG 2hPG FCP 2hCP
Regression 
coefficient
-0.001 -0.072 0.002 -0.085 -0.002 -0.033 0.133 0.116
P value 0.347 0.004 0.222 0.001 0.267 0.217 0.000 0.0001094 PENG DUAN ET AL.
related with the lumbar spine BMD and left femoral 
neck BMD (Table 2). The other variables, such as age, 
BMI, FPG and 2hPG had no association with lum-
bar spine BMD and left femoral neck BMD (P >0.05; 
Table 2).
Furthermore,  multiple  regression  analysis  was 
performed with lumbar spine and left femoral neck 
BMD as dependent variables and the other relevant 
factors as independent variables. The analysis results 
indicated that the duration of diabetes (r = -0.072, 
P = 0.004), HbA1c (r = -0.085, P = 0.001), FCP (r 
= 0.133, P = 0.000) and 2hCP (r = 0.116, P = 0.000) 
were directly associated with lumbar spine and left 
femoral neck BMD after adjusting BMI (Table 3). 
The other factors, such as age, BMI, FPG, and 2hPG 
were not correlated with lumbar spine and left femo-
ral neck BMD (P >0.05; Table 3).
DISCUSSION
In this study, the lumbar spine and left femoral 
neck BMD of patients with T1D were lower than 
those of the control group were. The BMD of lumbar 
spine and left femoral neck were reduced by 7.1% and 
7.3%, respectively. Mastrandrea et al. (2008) found 
that patients with T1D had reduced BMD and in-
creased risk of postmenopausal osteoporosis fracture 
by studying 63 cases of female patients with T1D, and 
Hamilton (2009) came to similar conclusions in Aus-
tralia. Some researchers have found that the BMD of 
premenopausal women with T1D was 3-8% lower 
than that of healthy women and that the risk of oste-
oporosis fracture increased (Strotmeyer et al., 2006). 
Therefore, the change in the BMD in patients with 
T1D was in conformity to the results of the above-
mentioned studies. However, some researchers have 
observed that there were minor differences in body 
composition, and no differences in BMD between 
healthy  controls  and  patients  with  long-standing 
childhood and adolescence onset T1D (Ingberg et 
al., 2004). These inconsistent conclusions may be re-
lated to the small sample size, i.e., only a few tens of 
cases. Collecting a large amount of studying subjects 
is actually quite difficult because the number of pa-
tients with T1D is small. In addition, genetic factors 
play very important roles in the BMD, and the results 
may be changed among different races and different 
areas (Travison et al., 2011).
This study found that the BMD of lumbar spine 
and left femoral neck were negatively correlated to 
the duration of disease and HbA1c, and positively 
related to the FCP and 2hCP. The complications of 
diabetes could lead to a decrease in BMD since the 
incidence rates of complications increase with the 
duration of diabetes. The level of HbA1c reflects the 
glycemic control of patients in recent 3 months. Gly-
cemic control will become worse and the BMD will 
be reduced when the level of HbA1c is increased. 
Heilman et al. (2009) have found that the BMD of 
patients with T1D was reduced and the lower BMD 
was  associated  with  poor  glycemic  control.  Nev-
ertheless,  some  researchers  considered  that  blood 
glycemic control and diabetes duration could not in-
fluence the BMD of patients with T1D (Hadjidakis 
et al., 2006). Because the level of C peptide reflects 
the function of islet β cells and the endogenous in-
sulin secretion which have a relationship with BMD, 
the level of C peptide of patients in T1D is related 
to the BMD (Rakel et al., 2008). With regard to the 
mechanism  of  the  reduced  BMD  of  patients  with 
T1D, studies have found that the levels of IL-6 and 
IL-8 of patients with T1D rose and the levels of BMD 
and  IGF-1  (insulin-like  growth  factor-1)  fell,  and 
the lower level of BMD in patients with T1D was 
associated with worse glycemic control and higher 
levels  of  inflammatory  factors  (AboElAsrar  et  al., 
2012; Joshi et al., 2013). Rachon et al. (2003) found 
that the BMD and IL-6 of postmenopausal patients 
with T1D were increased and reduced respectively, 
which also indicated that the BMD of patients with 
T1D may be related to autoimmunity and the levels 
of inflammatory factors. In addition, some studies 
have found that vitamin D receptor-gene polymor-
phisms are closely related to BMD in patients with 
T1D (Kocabas et al., 2010; Pesta, 2012). The BMD of 
patients with T1D also has a close relationship with 
diabetes complications, antidiabetic drugs, glycemic 
control and life style. Therefore, other parameters, 
such as calcium, phosphorus, albumin, creatinine, 
25-hydroxy vitamin D3, need to be further analyzed BONE MINERAL DENSITy IN DIABETES 1095
to observe the factors related to the bone metabolism 
of patients with T1D.
In a word, the BMD of patients with type 1 dia-
betes is reduced and BMD is related to the duration 
of diabetes and the levels of HbA1c and C peptide. 
The results of our study provide some reference to 
the treatment of osteoporosis of patients with T1D 
and  may  facilitate  the  taking  of  effective  counter-
measures; the specific mechanism still needs to be 
further studied with larger sample size.
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